Albendazole induces the terminal differentiation of acute myeloid leukaemia cells to monocytes by stimulating the Krüppel-like factor 4-dihydropyrimidinase-like 2A (KLF4-DPYSL2A) axis.
Mina NouraKen MoritaHiroki KiyoseYukiko OkunoHidemasa MatsuoAsami KoyamaYoko Nishinaka-AraiYasuhiko KamikuboSouichi AdachiPublished in: British journal of haematology (2021)
Differentiation therapy is a less toxic but still a very effective treatment for a subset of acute myeloid leukaemia (AML) cases. With the goal to identify novel compounds that can effectively and safely induce the terminal differentiation of non-acute promyelocytic leukaemia (APL) AML cells, we performed a chemical screening and identified albendazole (ABZ), a widely used anti-helminthic drug, as a promising lead compound that can differentiate non-APL AML cells by stimulating the Krüppel-like factor 4-dihydropyrimidinase-like 2A (KLF4-DPYSL2A) differentiation axis to the monocytes. Our in vitro and in vivo findings demonstrate that ABZ is an attractive candidate drug as a novel differentiation chemotherapy for patients with non-APL AML.
Keyphrases
- acute myeloid leukemia
- induced apoptosis
- liver failure
- cell cycle arrest
- dendritic cells
- drug induced
- respiratory failure
- allogeneic hematopoietic stem cell transplantation
- endoplasmic reticulum stress
- transcription factor
- cell death
- aortic dissection
- stem cells
- squamous cell carcinoma
- immune response
- intensive care unit
- peripheral blood